News For SGEN From The Last 14 Days Check below for free stories on SGEN the last two weeks.
There are 3 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 9, 2010
|
| 16:20 EDT |  | SGEN |
| | 16:19 EDT | | SGEN |
| theflyonthewall.com: | Seattle Genetics reports Q4 EPS (12c) vs. consensus of (23c) | | Reports Q4 revenue $21.8M vs. consensus of $11.71M. :theflyonthewall.com |
|
|
February 3, 2010
|
| 09:03 EDT |  | SGEN |
| theflyonthewall.com: | Seattle Genetics and Millenium announce phase 1 combination clinical trial | | Seattle Genetics and Millennium Pharmaceuticals announced that they have initiated a phase I clinical trial of brentuximab vedotinin combination with chemotherapy for the treatment of newly diagnosed Hodgkin lymphoma patients. Brentuximab vedotin is an antibody-drug conjugate that is also in single-agent clinical trials, including a pivotal trial for relapsed and refractory Hodgkin lymphoma and a phase II trial for systemic anaplastic large cell lymphoma. The target for brentuximab vedotin is CD30, which is expressed on these hematologic malignancies. The phase I combination trial will evaluate brentuximab vedotin plus Adriamycin, bleomycin, vinblastine and dacarbazine, a commonly used front-line chemotherapy regimen for Hodgkin lymphoma. :theflyonthewall.com |
|
|
|
Subscribe for More Information